TY  - JOUR
AB  - Following publication of the original article [1], the authors reported an error in Table 5. In Table 5 of our paper [1], we incorrectly cited part of the work of Lassmann and Nosske [2] by giving the value of 3.6 mGy/MBq for the liver absorbed dose coefficient due to alphas after intravenous administration of 223Ra-chloride. The correct value should be 36 mGy/MBq. Consequently, the following text in page 13 of our paper [1] has to be amended: “The results of the present study were compared to the results of the compartmental modelling of Lassmann and Nosske [20] and were found to be lower (skeletal doses by a factor of 2.3–3.4, colon dose by a factor of 7.2), except for the doses to liver and kidneys, which were found to be higher by a factor of ca. 7.” Amended text: “The results of the present study were compared to the results of the compartmental modelling of Lassmann and Nosske [20] and were found to be lower (skeletal doses by a factor of 2.3–3.4, colon dose by a factor of 7.2), except for the dose to kidneys, which was found to be higher by a factor of ca. 7. The dose coefficient to the liver shows a good agreement with the dose estimated by Lassmann and Nosske [2]”. The authors thank Lassmann and Eberlein for pointing out this error [3] and apologize for the incorrect citation. The original article [1] has been updated.
AU  - Höllriegl, V.
AU  - Petoussi-Henß, N.
AU  - Hürkamp, K.
AU  - Ocampo Ramos, J.C.*
AU  - Li, W.B.
C1  - 73148
C2  - 56928
CY  - One New York Plaza, Suite 4600, New York, Ny, United States
TI  - Correction: Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer.
JO  - EJNMMI Phys.
VL  - 12
IS  - 1
PB  - Springer
PY  - 2025
SN  - 2197-7364
ER  - 

TY  - JOUR
AB  - Purpose Ra-223-Dichloride (223Ra, Xofigo®) 
      is used for treatment of patients suffering from castration-resistant 
      metastatic prostate cancer. The objective of this work was to apply the 
      most recent biokinetic model for radium and its progeny and dosimetric 
      framework developed by the International Commission on Radiological 
      Protection (ICRP) and to show their radiopharmacokinetic behaviour. 
      Organ absorbed and equivalent doses after intravenous injection of 223Ra were estimated and compared to clinical data and other modelling study.Methods The most recent ICRP systemic biokinetic model of 223Ra
       and its progeny as well as the ICRP human alimentary tract model were 
      applied for the radiopharmacokinetic modelling of Xofigo® 
      biodistribution in patients after bolus administration. Independent 
      kinetics was assumed for the progeny of 223Ra. The time activity curves for 223Ra
       were modelled and the time integrated activity coefficients, in the 
      source regions for each progeny were determined. For estimating the 
      organ absorbed doses, the Specific Absorbed Fractions (SAF) and 
      dosimetric framework of ICRP were used together with the aforementioned 
      values to estimate the organ absorbed and equivalent doses.Results The distribution of 223Ra
       after injection showed a rapid plasma clearance and a low urinary 
      excretion. Main elimination was via faeces. Bone retention was found to 
      be about 30% at 4 h post-injection. Similar tendencies were observed in 
      clinic trials. The highest absorbed dose coefficients were found for 
      bone endosteum, liver, and red marrow, followed by kidneys and colon.Conclusion The biokinetic modelling of 223Ra
       and its progeny may help to predict their distributions in patients 
      after administration of Xofigo®. The organ dose coefficients of this 
      work showed some variation to the values from clinical studies and of a 
      previous compartmental modelling study. The dose to the bone endosteum 
      was found to be lower by a factor of ca. 3 than previously estimated.
AU  - Höllriegl, V.
AU  - Petoussi-Henß, N.
AU  - Hürkamp, K.
AU  - Ramos, J.C.O.*
AU  - Li, W.B.
C1  - 61254
C2  - 49785
CY  - One New York Plaza, Suite 4600, New York, Ny, United States
TI  - Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration resistant prostate cancer.
JO  - EJNMMI Phys.
VL  - 8
IS  - 1
PB  - Springer
PY  - 2021
SN  - 2197-7364
ER  -